Choosing medications for treatment-resistant depression based on mechanism of action

Journal of Clinical Psychiatry

Volumn 76, Issue 6, 2015, Pages 720-727

  Thase, Michael E ^a   Schwartz, Thomas L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; DOPAMINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN; NOREPINEPHRINE DOPAMINE REUPTAKE INHIBITOR; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VILAZODONE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

AMYGDALOID NUCLEUS; BLURRED VISION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; FRONTAL LOBE; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; MAJOR DEPRESSION; NAUSEA; PREFRONTAL CORTEX; PRIORITY JOURNAL; PRURITUS; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SUICIDAL BEHAVIOR; TACHYCARDIA; TREATMENT RESISTANT DEPRESSION; WEIGHT GAIN; XEROSTOMIA; AGONISTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS; NEUROTRANSMITTER AGENTS;

EID: 84932605875     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14052ah2c     Document Type: Review

References (34)

1. Knoth RL, Bolge SC, Kim E, et al. Effect of inadequate response to treatment in patients with depression. Am J Manag Care. 2010;16(8):e188-e196. PubMed
2. Romera I, Pérez V, Ciudad A, et al. Residual symptoms and functioning in depression, does the type of residual symptom matter? a post-hoc analysis. BMC Psychiatry. 2013;13(1):51. doi:10.1186/1471-244X-13-51 PubMed
3. Gartlehner G, Hansen RA, Thieda P, et al. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
4. Nandi A, Beard JR, Galea S. Epidemiologic heterogeneity of common mood and anxiety disorders over the lifecourse in the general population: a systematic review. BMC Psychiatry. 2009;9(1):31. doi:10.1186/1471-244X-9-31 PubMed
5. rd ed. New York, NY: Cambridge University Press; 2008.
6. Sonawalla SB, Rosenbaum JF. Placebo response in depression. Dialogues Clin Neurosci. 2002;4(1):105-113. PubMed
7. Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:54-63. doi:10.1016/j.pnpbp.2013.04.009 PubMed
8. Prins J, Olivier B, Korte SM. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opin Investig Drugs. 2011;20(8):1107-1130. doi:10.1517/13543784.2011.594039 PubMed
9. Korte SM, Prins J, Krajnc AM, et al. The many different faces of major depression: it is time for personalized medicine. Eur J Pharmacol. 2015;753:88-104. doi:10.1016/j.ejphar.2014.11.045 PubMed
10. Lane RM. Antidepressant drug development: focus on triple monoamine reuptake inhibition [published online ahead of print October 14, 2014]. J Psychopharmacol. 2014. doi:10.1177/0269881114553252 PubMed
11. Hirschfeld RMA. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61(suppl 6):4-6. PubMed
12. Robinson DS. The role of dopamine and norepinephrine in depression. Prim Psychiatry. 2007;14(5):21-23.
13. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64(3):327-337. doi:10.1001/archpsyc.64.3.327 PubMed
14. Schatzberg AF. New approaches to managing psychotic depression. J Clin Psychiatry. 2003;64(suppl 1):19-23. PubMed
15. Drevets WC. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci. 1999;877:614-637. doi:10.1111/j.1749-6632.1999.tb09292.x PubMed
16. Monkul ES, Silva LA, Narayana S, et al. Abnormal resting state corticolimbic blood flow in depressed unmedicated patients with major depression: a (15) O-H(2)O PET study. Hum Brain Mapp. 2012;33(2):272-279. doi:10.1002/hbm.21212 PubMed
17. Bauer M, Pfennig A, Severus E, et al, for the Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334-385. doi:10.3109/15622975.2013.804195 PubMed
18. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Arlington, VA: American Psychiatric Association; 2010. PubMed
19. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737-748. doi:10.1038/sj.bjp.0707253
20. Stewart JW, Thase ME. Treating DSM-IV depression with atypical features. J Clin Psychiatry. 2007;68(4):e10. doi:10.4088/JCP.0407e10 PubMed
21. Nordqvist C. What are antidepressants? http://www.medicalnewstoday.com/articles/248320.php. Updated September 15, 2014. Accessed May 5, 2015.
22. Chee KY, Tripathi A, Avasthi A, et al. International study on antidepressant prescription pattern at 40 major psychiatric institutions and hospitals in Asia: a 10-year comparison study [published online ahead of print February 23, 2015]. Asia Pac Psychiatry. doi: 10.1111/appy.12176.
23. Hawton K, Bergen H, Simkin S, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry. 2010;196(5):354-358. doi:10.1192/bjp.bp.109.070219 PubMed
24. Gibbons RD, Hur K, Bhaumik DK, et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry. 2005;62(2):165-172. doi:10.1001/archpsyc.62.2.165 PubMed
25. Thase ME. Are SNRIs more effective than SSRIs? a review of the current state of the controversy. Psychopharmacol Bull. 2008;41(2):58-85. PubMed
26. Martinez JM, Katon W, Greist JH, et al. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int Clin Psychopharmacol. 2012;27(1):17-26. doi:10.1097/YIC.0b013e32834ce11b PubMed
27. nd ed. Published 2005. http://psychiatryonline.org/pb/assets/raw/sitewide/practice-guidelines/guidelines/bpd-watch.pdf. Accessed May 5, 2015.
28. Thase ME. Depression and sleep: pathophysiology and treatment. Dialogues Clin Neurosci. 2006;8(2):217-226. PubMed
29. Oleptro (trazodone)[package insert]. Gaithersburg, MD: Angelini Pharma; 2010. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88c45123-f475-4dd0-bbac-c261868924ef. Accessed May 5, 2015.
30. Nefazodone [package insert]. Sellersville, PA: Teva Pharmaceuticals; 2003. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51ff7db5-aaf9-4c3c-86e6-958ebf16b60f. Accessed May 5, 2015.
31. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009;14(10):536-546. PubMed
32. Croft HA, Pomara N, Gommoll C, et al. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2014;75(11):e1291-e1298. doi:10.4088/JCP.14m08992 PubMed
33. Brintellix (vortioxetine)[package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2013. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3#nlm34084-4. Accessed May 5, 2015.
34. Leiser SC, Li Y, Pehrson AL, et al. Serotonergic regulation of prefrontal cortical circuitries involved in cognitive processing: a review of individual 5-HT receptor mechanisms and concerted effects of 5-HT receptors exemplified by the multimodal antidepressant vortioxetine [published online ahead of print March 6, 2015]. ACS Chem Neurosci. doi:10.1021/cn500340j PubMed